-
ACLA White Paper: Considerations for Appropriate Use of SARS-CoV-2 Testing
-
ACLA Comments on MCIT/Reasonable and Necessary Definition Proposed Rule
-
ACLA Comments on United States Core Data for Interoperability (USCDI) Draft V2
-
ACLA Comments on Medicare Coverage of Innovative Technology (MCIT)
-
ACLA Letter To Senate Finance Committee On Xavier Becerra’s Nomination
-
ACLA Letter To Biden Administration On COVID Testing
-
ACLA Letter to New York State on Executive Order
-
Joint Letter on Cycle-Threshold Value Reporting
-
ACLA Comment Letter on Reconsideration Request for New Therapeutic Drug and Molecular Pathology CPT Codes
-
ACLA Letter on COVID Vaccine Distribution
